|
|
|
|
Wednesday, August 14, 2019
electroCore (ECOR)
Soothing Investors’ Migraine a Bit?
electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Ahu Demir, Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Revenue is growing. The company reported $0.6 million of revenue (+52%), 1,000 paid prescriptions (+52%) and 2,451 prescribing physicians (+11%) in this quarter relative to the previous quarter.
- Calming of chopping waters. We believe the recent numbers represent a positive trend, following multiple gloomy news in previous quarter. The current revenue ramp-up was driven by…
Get full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.